Understanding the Short Seller's Claims Against Praxis Precision
A short seller has recently raised serious concerns regarding Praxis Precision Medicines Inc. (NASDAQ: PRAX) after the company announced what it deemed successful results from its Phase 3 trial for ulixacaltamide.
According to reports, shares of PRAX have been declining, reflecting growing skepticism about the validity of the clinical data presented.
Culper Research, the short-selling firm in question, argues that the findings supporting Praxis's essential tremor program are too flawed to withstand rigorous regulatory scrutiny.
The short report posits that Praxis allegedly manipulated the results of its October 2025 trials through strategic decisions aimed at inflating the drug's perceived effectiveness.
Phase 3 Trial Results: What Was Reported?
Praxas announced topline outcomes for its Phase 3 Essential3 trial concerning ulixacaltamide for essential tremor (ET).
Key Findings from the Study
The initial study revealed a significant and clinically relevant improvement in the mADL11 score, showing a 4.3 point enhancement at Week 8, with a p-value of less than 0.0001.
This improvement reportedly continued consistently from Week 2 to the end of the 12-week treatment period, with all major secondary endpoints also achieving statistical significance.
Despite these positive indicators, skepticism lingers. The short seller claims that the results were selectively reported and manipulated in light of participant dropouts, suggesting that nearly 36% of patients who left the trial may have skewed the outcome in Praxis's favor.
Concerns About Regulatory Oversight
Culper Research claims significant concerns exist regarding the adjustments made by Praxis, specifically about changes to the primary endpoint that may have never received FDA approval.
The report further indicates that some of the statistical methods employed contradicted previous research citations made by Praxis, raising alarms about the integrity of the study's findings.
Expert Opinions on Ulixacaltamide's Future
To support their claims, Culper Research consulted several experts, including ex-directors at Praxis and former FDA officials, to validate the assertion that ulixacaltamide lacks a solid approval pathway.
As the company gears up for an upcoming pre-NDA meeting, the report warns that regulators are likely to uncover substantial issues that might pose a considerable downside risk for the stock.
The Valuation Dilemma
Praxis has heavily depended on the potential success of ulixacaltamide, a drug it acquired for a mere $1 million in 2018. This low initial investment raises eyebrows, reflecting doubts about the drug's viability in the market.
The short seller emphasizes that nearly all of Praxis's current market capitalization is hinged on ulixacaltamide's success, estimated at a value of around $3 billion—integral to achieving their target of approximately $4.5 billion in market cap.
Investor Reaction and Market Trends
Following the announcements, shares of Praxis Precision Medicine experienced a decline, marking a 9.10% drop, with stock prices recorded at approximately $172.10.
While many analysts remain optimistic, predicting an 80% chance of ulixacaltamide's approval, the underlying concerns about its stability and the broader implications for other similar drugs loom large.
This sentiment has led some to describe the drug’s prospects as a fragile structure, echoing the sentiment of calling it 'a house of cards.'
Frequently Asked Questions
What are the main allegations against Praxis Precision Medicines?
The main allegations include the manipulation of trial data and changes to primary endpoints that may not have received FDA approval.
How did the market react to the claims made by the short seller?
The market reacted negatively, with shares of Praxis Precision Medicines decreasing significantly following the allegations.
What is ulixacaltamide?
Ulixacaltamide is a drug developed by Praxis Precision Medicines that is currently undergoing trials for treating essential tremor.
What do experts say about ulixacaltamide's approval chances?
While some experts maintain a hopeful outlook, others question its viability, citing numerous issues that could hinder FDA approval.
Where can I find more information on this topic?
Further information may be available through financial news outlets or direct updates from Praxis Precision Medicines.
